Intellia Therapeutics Narrows Q4 Loss to $0.83, Tops Revenue Estimates
Intellia Therapeutics narrowed its Q4 2025 loss to $0.83 per share, beating the analyst consensus loss estimate of $0.99 and improving from a $1.24 loss a year earlier. The company also reported revenue that topped analyst forecasts.
1. Q4 2025 Financial Results
Intellia Therapeutics reported a Q4 2025 GAAP loss of $0.83 per share, outperforming the analyst consensus loss estimate of $0.99. Revenue for the quarter exceeded forecasts, marking a positive deviation from expectations.
2. Year-Over-Year Improvement
The cash burn narrowed significantly as the per-share loss improved from $1.24 in Q4 2024 to $0.83 in Q4 2025, reflecting tighter cost controls and potential early contributions from advancing pipeline programs.
Related News
NEWP
Bolivia Overhauls Regulations as New Pacific Metals Poised for $700 Million Mining Boost
NEWP•
MA
Chargebacks911 Partners with acceptcards to Reduce Chargebacks as UK Card Use Tops £1 Trn
MA•
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
TGT
Target CEO Highlights Under-$10 Toy Sales Surge Despite High Costs
TGT•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
Sources
FZ